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Introduction 
 INTRODUCTION 
The term “non-fermenters”(NFs) refers to a group of aerobic, nonspore 
forming Gram negative bacilli (GNB) that are either incapable of utilizing 
carbohydrate as a source of energy or degrade them via “oxidative” rather 
than fermentative pathways.55 
In addition, they possess cytochrome  oxidase activity and fail to grow 
or grow poorly on MacConkey agar.14 Although frequently considered to be 
commensals or contaminants, the pathogenic potential of non-fermenters has 
been established beyond doubt by their recurrent isolation from clinical 
materials and their association with human disease.3  
The critically ill patients receiving life saving therapy in Intensive care 
unit (ICU) often requires broad spectrum antibiotics, insertion of various 
indwelling devices, nutritional support and immuno-suppressive therapy.9 
These factors along with underlying debility and immunosuppression account 
for the fact that though only 5-10% of all hospital beds are in ICU, these 
patients happen to be victims of over 20% of all hospital acquired infections. It 
is in this modern context of intensive treatment that the importance of non-
fermenters as a nosocomial pathogen has increased.21 
Pseudomonas aeruginosa is one of the main pathogenic agent in this 
group and ranks second among all pathogens evidenced in prevalence of 
infections in Intensive care study.27 Ventilator associated pneumonia caused 
by this microorganism remains a severe and dreaded complication.20 
Acinetobacter is now been increasingly recognized as cause of 
respiratory tract infection in ICU patients with Acinetobacter baumanii is the 
commonest species.29 Other non-fermenter which is gaining importance in 
 ICU patients is Stenotrophomonas maltophilia. This is associated with 
increased length of ICU stay, duration of mechanical ventilator support and  
mortality among patients with ventilator associated pneumonia.49 
P.aeruginosa is a classical opportunistic pathogen with innate 
resistance  to many antibiotics.6 An alarming increase in the resistance to 
various  antimicrobial agents have been reported from India and abroad. They 
exhibit  alarming levels of resistance to even most recent antibiotics like third  
generation cephalosporins, antipseudomonal penicillins (Piperacillin, 
Ticarcillin), aminoglycosides and fluoroquinolones. 13,19 
Resistance to these agents can arise by various mechanisms including 
mutational depression of AmpC chromosomal beta-lactamases, acquisition of 
secondary plasmids or transposon mediated beta-lactamases, reduced 
permeability or multidrug efflux25 or in case of imipenem via, loss of D2 
porin.11 
The introduction of Carbapenems (meropenem, imipenem) into clinical 
practise represented a greater advance for treatment of serious bacterial 
infections caused by beta –lactam resistant bacteria. However, carbapenem 
resistance has been frequently observed in non-fermenting bacilli like 
P.aeruginosa and Acinetobacter species. The common form of resistance is 
mediated by lack of drug penetration and/or carbapenem-hydrolysing beta-
lactamases.25 In this study importance in isolation of non-fermenting gram 
negative bacilli(NFGNB) and establish their pathogenesis by repeat isolation, 
to speciate the isolates and study their susceptibility patterns and to 
determine the presence of metallo-betalactamase (MBL) producing 
Pseudomonas from patients admitted to ICU are discussed. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
 REVIEW OF LITERATURE 
The group of non-fermenters include several genera and species of 
bacteria with special growth requirements and the dividing line between what 
is a “non-fermenter” and what may otherwise be designated as “fastidious” 
non-glucose fermenting GNB is based more on convention than on well-
defined genetic or phenotypic characteristics.30 As these organisms are 
inhabitants of environment and they occurred on body surface and mucous 
membranes, until recently ,a number of  non-fermenters were looked upon as 
non-pathogenic commensals of little clinical significance. But recently, there 
has been a tremendous interest in these organisms as they can cause 
disease by colonizing and subsequently infecting immunocompromised   
individuals. The pathogenic potential of non-fermenters is established beyond 
doubt by their repeated isolation from clinical samples and their association 
with disease.3 
The range of infections caused by these organisms vary from 
cutaneous infections to primary bacteremias. Urinary tract infections(UTI), 
post-operative wound infections, pneumonias and primary bacteremias make 
upto 80-90% of  reported infections. The commonly acquired non-fermenters 
in community based as well as hospitalized patients are Pseudomonads 
species, Acinetobacter, Alcaligenes and Stenotrophomonas maltophilia.55 
 MEDICALLY  IMPORTANT  NON-FERMENTERS 
Motile with polar flagella, Oxidase Positive 
Family  Pseudomonadaceae 
(rRNA group 1) 
Genus Pseudomonas   (except P.luteola, P.oryzihabitans) 
Family Burkholderiaceae 
(rRNA group 2) 
Genus Burkholderia  (except B.cepacia complex, B.gladioli) 
Genus Cupriavidus 
Genus Lautropia 
Genus Pandoraea 
Genus Ralstonia 
Family Comamonadaceae 
(rRNAgroup 3) 
Genus  Comamonas 
Genus  Acidovorax 
Genus  Delftia 
Family Caulobacteraceae 
(rRNAgroup 4) 
Genus Brevundimonas 
Family Xanthomonadaceae 
(rRNA group5) 
Genus Stenotrophomonas  (except S.maltophilia) 
 
 Family Sphingomonadaceae 
Genus Sphingomonas 
Family Oceanospirillaceae 
Genus Balneatrix 
Family Alteromonadaceae 
Genus Alishewanella 
Genus Shewanella 
Family Oxalobacteraceae 
Genus Herbaspirillum 
Genus Massilia 
Family Methylobacteriaceae 
Genus Methylobacterium 
Genus Roseomomas 
 
Motile with peritrichous flagella  
Family Alcaligenaceae 
Genus Achromobacter 
Genus Alcaligenes 
Genus Bordetella (B.avium, B.bronchiseptica, B.hinzii) 
Genus Kerstersia 
Genus Oligella (O.ureolytica) 
Family Rhizobiaceae 
Genus Rhizobium 
Family Brucellaceae  
Genus Ochrobactrum 
 Family Halomonadaceae 
Genus Halomonas 
Nonmotile, Oxidase Positive  
Family  Flavobacteriaceae 
Genus Flavobacterium 
Genus Bergeyella 
Genus Chryseobacterium 
Genus Empedobacter 
Genus Myroides 
Genus Weeksella 
Family Sphingobacteriaceae 
Genus Sphingobacterium 
Genus Pedobacter 
Family Moraxellaceae 
Genus Moraxella 
Genus Psychrobacter 
Family Neisseriaceae 
Genus Neisseria 
Family Alcaligenaceae 
Genus Oligella (O.urethralis) 
Family Rhodobacteraceae 
Genus Paracoccus 
 Nonmotile, Oxidase – Negative  
Family Moraxellaceae 
Genus Acinetobacter 
Family Alcaligenaceae 
Genus Bordetella(B.pertussis,B.parapertussis,B.trematum) 
Organism  whose taxonomic position is uncertain 
CDC group NO-1 
CDC group EO-5 
INITIAL CLUES THAT AN UNKNOWN ISOLATE IS A NON-
FERMENTER 
 Lack of evidence for glucose fermentation. 
 Positive cytochrome oxidase test. 
 Failure to grow on MacConkey agar. 
Lack Of Evidence For Glucose Fermentation 
          Acid produced by NFs are considerably weaker than mixed acids 
derived from fermentative bacteria, thus the pH in fermentation test media in 
which a NF is growing may not drop sufficiently to convert the pH indicator. 
The initial clue that an unknown organism is a NF is usually the lack of acid 
production in either Triple sugar iron(TSI) or Kligler iron agar(KIA) media, 
manifested as an alkaline slant and an alkaline deep.31 
 Positive Cytochrome Oxidase Reaction  
          Any colony of a GNB growing on blood agar or any other primary 
isolation media that is cytochrome oxidase positive can be suspected of 
belonging to NF group. To test the oxidase activity of NFs, CDC recommends 
using a 0.5% aqueous solution of tetramethyl p-phenylene diamine 
dihydrochloride. A few drops of reagent can be used to flood the surface of 
agar medium on which bacterial colonies are growing. The development of 
blue color within a few seconds indicate a positive test. Negative test can be 
confirmed using the more sensitive Kovac’s method, in which loopful of 
organisms is mixed with few drops of 1% tetramethyl p-phenylene diamine 
dihydrochloride reagent on a piece of filter paper. The development of dark 
blue color in 10 seconds indicates a positive test.31 
Failure To Grow On MacConkey Medium 
           GNB that grows on blood agar but poorly or not at all on Macconkey 
agar should be suspected of belonging to NF group.31 
TESTS  USED  FOR  IDENTIFICATION  OF  NON-FERMENTERS31 
Utilisation  Of  Glucose 
Hugh-Leifson Oxidative-Fermentative(OF) medium is recommended to 
detect the metabolic properties  of  NFGNB. Two tubes of each carbohydrate 
medium are required for the test. The medium in one tube is exposed to air; 
the other is overlaid with sterile mineral oil or melted paraffin. Oxidative 
organisms produce acid only in the open tube exposed to atmospheric 
oxygen; fermenting organisms produce acid in both the tubes; and non-
 saccharolytic organisms are inert in both the tubes, which remains at an 
alkaline pH after incubation. 
Motility 
The hanging drop preparation may be more accurate in detecting 
motility of NFGNB. A loopful of 6 to 24 hr, actively growing broth culture that 
has been incubated at 37oC is placed in the center of No-1 coverslip that is 
inverted and suspended over the concavity of depression slide. True motility 
must be differentiated from Brownian movement. Motile bacteria show 
directional movement and change in position relative to each other; when 
Brownian movement is the cause of motion, they maintain the same relative 
position. Motility B medium with tetrazolium also used for demonstrating  
motility of NFGNB. Flagellar stains can also be used to demonstrate motility. 
Pigment Production 
Pseudomonas produce water-soluble and diffusible pigments like 
fluorescein (pyoverdin), pyocyanin, pyorubin, pyomelanin that discolor the 
culture media. “Tech” and “Flo” media were developed to enhance the 
formation of water-soluble pigments pyoverdin and pyocyanin. These media 
have special peptones and an increased concentration of magnesium and 
sulfate ions to enhance pigment production. Pigment production also 
enhanced by growing the organism in gelatin, potato or milk-containing media 
and by incubating them at 25 –30oC. 
Hydrolysis Of Urea 
Christensen’s urea agar slants used. Bacterial species like Bordetella 
bronchiseptica produce a red color change within 4hours; weak reactors may 
require up to 48 hours. 
 Nitrate Reduction 
The ability of the organisms to reduce nitrate to nitrite is an important 
characteristic used in the identification and speciation of many 
microorganisms. Organisms demonstrating nitrate reduction have the 
capability of extracting oxygen from nitrate to form nitrite and other reduction 
products. The presence of nitrite in the test medium is detected by the 
addition of alpha-naphthylamine and sulphanilic acid  which leads to the 
development of red color. If red color do not develop, either nitrate has not 
been reduced or reduction is beyond the nitrite stage to the formation of other 
compounds or to nitrogen gas (denitrification). The appearance of red color on 
addition of small quantity of zinc dust indicates the residual presence of 
nitrate, denoting a negative test; absence of color indicates nitrate has been 
reduced beyond nitrite, indicating the original test was positive. 
Denitrification  of  Nitrates And Nitrites 
Certain nonfermenters have the capability of reducing nitrate or nitrite 
or both to gaseous nitrogen. Nitrate-nitrite broth with an inverted Durham tube 
may be used.  Because the media contains no carbohydrate, any gas that is 
formed is derived from nitrate or nitrite, indicating a positive reaction. 
Indole Production 
An enriched tryptophan –containing media, usually heart infusion broth 
may be needed. Because only small quantities of Indole are formed by some 
NFs, extraction of culture media by layering a small quantity of xylene or 
chloroform on the surface may be helpful. The appearance of fuchsia red 
color at the surface of medium with the reagent (kovac or Ehrlich reagent) 
indicates indole formation and a positive test.  One organism, Delftia 
 acidovorans, produces a distinctive “pumpkin orange” indole reaction owing to 
the formation of anthranilic acid rather than indole from tryptophan.             
Citrate Utilisation 
A well isolated colony is picked from the surface of a primary 
inoculation plate and inoculated as a single streak on the slant surface of 
Simmon’s citrate medium and incubated at 35oC for 24 to 48 hours. 
Development of blue color indicates a positive test. 
Decarboxylation 
Moeller decarboxylase medium is used. The development of alkaline 
purple color, following inoculation with the test organism and incubation at 
35oC for 24-48 hours indicates a positive test result. 
Esculin  Hydrolysis 
This is used primarily as a differential characteristic to distinguish 
between the two Brevundimonas species and some of the yellow pigmented 
pseudomonads. An esculin medium without bile is used for nonfermenters, 
because some of them are inhibited by bile. Esculin agar slants are inoculated 
with an unknown isolate and incubated at 35oC for 24-48 hours. Esculin in the 
medium fluoresces when observed with a wood’s lamp. When esculin is 
hydrolysed, the medium turns reddish –black and fluorescence is lost, 
indicating a positive test. 
 CHARACTERISTICS OF INDIVIDUAL ORGANISMS 
PSEUDOMONADS 
The Genus pseudomonas and closely related genera which were 
formerly placed in the Genus pseudomonas are referred to as 
pseudomonads. Pseudomonads are straight or slightly curved, aerobic, gram-
negative bacilli motile by means of polar flagella and utilize glucose and other 
carbohydrates oxidatively and are usually cytochrome oxidase positive. Most 
are saprophytes found widely in soil, water and other moist environments. 31 
Molecular analysis led to revised taxonomic classification  and many 
species have been reallocated to new genera which includes Burkholderia, 
Comamonas, Stenotrophomonas, Ralstonia and Brevundimonas. 24 
Palleroni separated pseudomonads into five ribosomal RNA homology 
groups based on r RNA-DNA homology studies.  
Gilardi on the other hand separated pseudomonads into seven major 
groups based on phenotypic characteristics 
 Fluorescent 
 Stutzeri 
 Alcaligenes 
 Pseudomallei 
 Facilis-delafieldii 
 Acidovorans 
 Diminuta 
 Pseudomonas species included in rRNA  group 1 includes 3 groups 
 Fluorescent  group 
 Stutzeri group 
 Alcaligenes group     
Fluorescent  Group 
The species within this group are characterized by the production of 
water-soluble pigment pyoverdin that fluoresces white to blue-green under UV 
light. This group includes P.aeruginosa, P.fluorescens and P.putida. Although 
all 3 species produce pyoverdin, only P.aeruginosa produces the distinctive 
blue water-soluble pigment pyocyanin. 30 
P.aeruginosa is the species most commonly associated with human 
disease. 24 There are several reasons for the prominence of P.aeruginosa as 
a human pathogen 
 Its adaptability 
 Its innate resistance to many antibiotics and disinfectants 
 Its armoury of putative virulence factors 
 An increasing supply of patient’s compromised by age, underlying 
diseases or immunosuppressive therapy. 24 
P.aeruginosa produces a characteristic appearance on Blood agar 
plate(BAP) and the colonies have an alligator skin appearance and exhibits a 
metallic sheen with beta-hemolysis. Rapid identification in culture can be 
made by  
  Typical colony morphology 
 Production of diffusible pigments  
 Presence of fruity odour  
 Positive oxidase. 
P.aeruginosa infection is prevalent among patients with burns, cystic 
fibrosis, acute leukemia, organ transplantation and intravenous drug addicts.10 
Infection commonly occurs at any site where moisture tends to accumulate- 
tracheostomies, indwelling catheters, burns, external ear and weeping 
cutaneous wounds. P.aeruginosa also causes urinary tract infections and 
lower respiratory tract infections, the later can be severe and life threatening 
in immunocompromised patients.30 The organism also causes keratitis. 
Analysis of bacterial keratitis reveals that Pseudomonas species is the second 
most important cause of bacterial keratitis in India after gram-positive 
bacteria.48 
P.aeruginosa produces several substances that are thought to 
enhance the colonization and infection of host tissues. These substances, 
together with the variety of virulence factors including lipopolysaccharide, 
exotoxin A, leucocidin, extracellular slime, proteases, phospholipases and 
several other enzymes make P.aeruginosa the most clinically significant 
bacteria among NFB. 30 An unususal mucoid morphotype of P.aeruginosa is 
recovered from respiratory secretions of patients with cystic fibrosis which is 
due to the production of large amounts of polysaccharide called alginate. The 
production of alginate is associated with poor prognosis and high mortality 
rates among patients with cystic fibrosis. 23 
 P.fluorescens and P.putida occur in water and soil and may exist in 
water sources in hospital environment. Both may exist as normal pharyngeal 
flora and are rare  opportunistic pathogens. Both the species fail to grow at 
42oC  as P.aeruginosa.  They produce only pyoverdin and not pyocyanin. 
Another character in which they differ from P.aeruginosa is that they do not  
deaminate acetamide. These two species differ from each other in gelatin 
hydrolysis where P.flourescens gives a positive reaction ; P.putida gives a 
negative reaction.30 P.putida has been reported to cause catheter-related 
sepsis in patients with cancer and septic arthritis. 37 
Treatment of P.aeruginosa infection is difficult because it express 
innate resistance to many antibiotics. An alarming increase in resistance to 
various antimicrobial agents has been reported from India and abroad.6 
Increased use of broad–spectrum antibiotics, intubation of respiratory, 
gastrointestinal or urinary tract and intravascular catheterization are significant 
predisposing factors for development of antibiotic resistance.28 They are found 
to be sensitive to aminoglycosides, antipseudomonal penicillin, 
fluoroquinolones, and third generation cephalosporins. Amikacin and 
ceftazidime were found to be highly effective.6 The incidence of meropenem–
resistant P.aeruginosa is also increasing among nosocomially infected 
patients in ICU.4 The potential risk factors are previous antimicrobial drug 
exposure. A growing number of multidrug resistant (MDR) P.aeruginosa 
producing metallo betalactamases (MBL) is also reported. Such strains are 
resistant to most broad spectrum beta-lactams, aminoglycosides and 
fluoroquinolones and the traditional antipseudomonal antimicrobials.2 The 
common form of drug resistance is mediated by lack of drug penetration 
(porin mutation and efflux pump) and/or cabapenem–hydrolysing beta-
lactamases. Based on molecular studies, carbapenem-hydrolysing enzymes 
 are classified into four groups A,B,C,D. The metallo betalactamases are 
enzymes requiring divalent cations as cofactors for enzyme activity, being 
inhibited by the action of a metal ion chelator.26 There are reports of MBL 
production in P.aeruginosa from various countries like Brazil, Korea, 
Singapore and France. MBL was first reported as a zinc dependent enzyme in 
Bacillus cereus in mid 1960s. A few decades later, meropenem hydrolyzing 
metalloenzymes were found in Aeromonas hydrophila and Bacteroides 
fragilis. All these enzymes were produced by chromosomal genes and at first 
recorded only from single clinical isolates. In 1991, Japan reported the first 
plasmid mediated MBL in P.aeruginosa. Apart from P.aeruginosa, other 
bacteria like Serratia, Klebsiella pneumonia, Escherichia coli, Enterobacter 
aerogenes, Enterobacter cloacae, Citrobacter freundii, Proteus vulgaris, 
P.putida, Acinetobacter and Alcaligenes xylosoxidans were also shown to 
produce MBL. These carbapenems may be class B MBL(VIM,IMP) or class D 
oxacillinases(OXA-23 to OXA-27) or class A clavulanic acid inhibitory 
enzymes(SME,NMC,IMI,KPC). They may be chromosomally or plasmid 
mediated and therefore possess a threat of spread of resistance by gene 
transfer among GNB. 43 Since carbapenem resistance is mediated by several 
mechanisms, cross-resistance is commonly seen among related antibiotics. 
Although there are various specific tests to detect the underlying mechanism 
of carbapenem resistance, Kirby-bauer disc diffusion test is a simple, easy to 
perform and cost-effective test which can be conveniently used to screen 
carbapenem resistance. These strains also remain resistant to several other 
antibiotics including penicillins, cephalosporins, quinolones, aminoglycosides 
and third generation cephalosporins including ceftazidime and cefotaxime. 
Thus, they may be ESBL producers as well. These MBLs effectively hydrolyse 
all betalactams except Aztreonam in vitro. This poses serious problems in 
 choosing the right antibiotic for treatment of sick patients admitted to ICU.43 
This disturbing situation could be attributed to the increased use of antibiotics 
which has to be controlled by strict antibiotic policy. Various strategies such 
as strict infection control measures, judicious prescribing of antibiotics, 
antibiotic resistance surveillance programs and antibiotic cycling must be 
tried. Regular monitoring and documentation of carbapenem resistance is 
therefore crucial in developing strategies to control infections due to these 
bacteria in patients admitted to ICU.  Therefore, detection of MBL-producing 
gram negative bacilli especially P.aeruginosa is crucial for the optimal 
treatment of patients particularly in critically ill and hospitalized patients and to 
control the spread of resistance. 
Extended spectrum metallo-betalactamases found in P.aeruginosa17 
Associated Phenotype, by drug Inhibition by 
Enzyme(s) 
Country 
where 
strains 
where found 
Emodement 
Site Carb-
Tic 
Pip-
Azl 
Czid Cpm-
Cpr 
Atm Imi- 
Mero 
Clv Taz 
PER-1 Turkey 
mostly, Italy, 
France, 
Belgium 
Plasmids (or) 
Chromosome  
R r R R R S Strong Weak 
OXA-11,-
14, -16, -19, 
-28 
Turkey 
(OXA-11, -
14&-16) 
France 
(OXA – 19 & 
-28) 
Integrins in 
Plasmids (or) 
Chromosome 
R R R R R S Weak Weak 
OXA – 15 Turkey Plasmids R R R R R S Weak Weak 
IMP -1 to -8 Japan (IMP-
1) 
Canada 
(IMP-7) 
Integrins in 
Plasmids (or) 
Chromosome 
R R R R S r/R No No 
VIM types Italy (VIM-1) 
France, 
Greece, 
Korea (VIM-
2), Taiwan 
(VIM-8) 
Integrins in 
Plasmids (or) 
Chromosome 
R R R R S r/R No No 
Azl-Azlocillin / Carb – Carbenicillin / Clv – Clavulanate / Cpm - Cefepime /  
Cpr – Cefpirome / Imi – Meropenem / Czid – Ceftazidime / Mero – Meropenem / Pip – 
Piperacillin / Taz – Tazobactam / Tic - Ticarcillin / r- reduced susceptibility / R- frank 
resistance / S – Susceptible / 
 Colonies of P.aeruginosa on Nutrient agar 
 
 
Brown Pigmented Pseudomonas 
 Typing Methods 
Typing procedures are useful for epidemiology, that is to establish the 
origin of strains causative of infections and are very important to guide 
treatment in environments of limited dimensions. 
Bacteriocin Typing 
Bacteriocins are proteins produced by some strains that are lethal 
against the cells of other strains of the same species. Pyocins, bacteriocins 
produced by P.aeruginosa, can be used to classify P.aeruginosa. There are 
three morphological types of pyocins. The R type resembles the tails of  
T-even coliphages and the F types are flexuous filaments. The third type, the 
S type, has low molecular weight, diffuses through the agar and has no 
discernible details under the electron microscope. The pyocin produced by an 
unknown strain is tested against a series of indicator strains. This is the most 
common method. In a variation, the pyocin sensitivity of the unknown is 
measured, instead of its production. Non-fluorescent pseudomonads are not 
sensitive to pyocins, but fluorescent members may be so. 54 
Serologic Typing 
The serological typing is based on the reaction of a heat stable  
O-antigen with a set of antisera initially proposed by Habs in 1957. Habs 
worked with 70 strains of bacteria and came up with 12 somatic groups, 
forming the basis of the International Antigenic Typing Scheme(IATS). Later 
there were several proposals to extend this number to reach 17 by addition of 
a few new small groups, but they were never accepted internationally. The 
antisera are prepared against live or boiled cell suspensions and in the 
agglutination reaction, boiled or autoclaved bacteria can be used. 54 
 DNA Restriction Analysis 
The endonucleases that are used in this type of analysis can be those 
that cut the DNA frequently or those that donot do so, a property that depends 
on the composition of the DNA and on the enzyme specificity. Pseudomonas 
is a taxon whose DNA is relatively rich in G+C pairs and will give more 
fragments after digestion with an enzyme having a high affinity for this 
configuration than with adenine and thymidine (A+T). For macro-restriction 
genome analysis, few bands are obtained by using enzymes that attack 
infrequently the DNA and in doing so, the fragments will be of large size and 
fewer in number. Their separation by electrophoresis will require special 
instrumentation. 54 
Vaccine Strategies against P.aeruginosa infection in the lung  
P.aeruginosa is an environmentally ubiquitous, extra cellular 
opportunistic GNB that causes significant morbidity and mortality to a 
disproportionately high degree for infections with this bacteria compared with 
other GNB. Patients at particular risk of infection are those with compromised 
respiratory function, in intensive care support and taking 
immunocompromising pharmaceutical agents. Once acquired, infection is 
difficult to eradicate with chemotherapy. Initial studies in an acute animal 
model clearly demonstrated that mucosal immunization with a killed whole 
bacterial cell preparation could induce protective immune responses in the 
lung. Subsequent studies have shown that the protective immune 
mechanisms were dependent on antigen specific CD4+ T Cells, the 
activations of alveolar macrophages, the recruitment and activation of 
polymorphs, predominantly neutrophils, the controlled secretion of TNF- 
alpha, IL-1 & IFN gama and the presence of antibody. A pre-clinical human 
 trial of an oral whole killed cell preparation has been completed with no 
adverse side effects. Preliminary analysis of the results has demonstrated that 
after oral vaccination, specific lymphocyte responses were observed to 
P.aeruginosa. 15 
Characteristics of fluorescent group  
Test P.aeruginosa P.fluorescens P.putida 
Oxidase + + + 
Motility + + + 
Pyoverdin + + + 
Pyocyanin + - - 
OF-glucose A A A 
Acetamide V + + 
Growth at 42 OC + - - 
Nitrate reduction V(74) V(19) - 
Arginine + + + 
 
+ , 90% (or) more strains positive / - , 90% (or) more strains negative / V , 11 
– 89 % of strains positive / A , acid reaction / ( ) numbers in the parenthesis 
are % of strains giving positive reactions.      
Stutzeri  Group 
The organism in this group – P.stutzeri, P.mendocina  and  CDCgroup 
Vb-3. These organisms are all soil denitrifiers and can grow anaerobically in 
nitrate containing media with the production of Nitrogen gas. They are motile 
by polar monotrichous flagella.30 They have been recovered from humus, 
manure, sewage, stagnant water, baby formulas, hospital equipments, eye 
cosmetics and various clinical specimens.22,40 It has been rarely associated 
 with infections like otitis media, conjunctivitis, pneumonia, infections of 
traumatic wounds and meningitis in Human Immunodeficiency Virus( HIV) 
patients. They are susceptibile to most antibiotics. 30 
Characteristics of stutzeri group  
Test 
P.stutzeri 
(VB-1) 
P.mendocina 
(VB – 2) 
CDC Group 
(VB – 3) 
Oxidase + + + 
Motility + + + 
OF-glucose A A A 
OF – maltose A - - 
Nitrate reduction + + + 
Nitrate to gas + + + 
Arginine - + + 
Polymyxin B S S S 
+ , 90% (or) more strains positive / - , 90% (or) more strains negative / A , acid 
reaction / S - Susceptible. 
 
Alcaligenes Group  
Organisms in this group are characterized by being assacharolytic or 
only weakly saccharolytic in OFglucose medium. Members of this group 
includes P.alcaligenes, P.pseudoalcaligenes and Pseudomonas species CDC 
group 1.30 There have been reports of P.alcaligenes causing eye infections, 
empyema and one case of fatal endocarditis. 55 
 Characteristics of alkaline Pseudomonads 
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Oxidase + + + + + + + 
Motility + + + + + + + 
OF-
Glucose 
Alk Weak Alk Alk Alk Weak Weak 
Nitrate 
reduction  
V (16) + + + + - - 
Nitrate to 
gas 
- - - - - - - 
Indole - - - - Orange - - 
 
+ , 90% (or) more strains positive / - , 90% (or) more strains negative / V , 11 
– 89 % of strains positive / Alk - alkaline reaction / ( ) numbers in the 
parenthesis are % of strains giving positive. 
ACINETOBACTER 
The Genus Acinetobacter is currently classified in the family 
Moraxellaceae and consists of bacteria that are non-motile, oxidase negative, 
gram-negative coccobacilli. Currently there are atleast 25 genomospecies in 
this genus. Genomospecies 1 is the type species and is named 
A.calcoaceticus. Genomospecies 2 is named as A.baumannii and 
Genomospecies8 is A.lwofii which are the commonly isolated species of 
Acinetobacter. A.baumannii is the second most frequently isolated non-
fermenter from clinical samples especially from patients in ICU next to 
P.aeruginosa.32 A.baumannii is a water organism and often isolated from 
 hospitalized patient’s sputum or respiratory secretions, wound and urine.1 
Acinetobacter infections are uncommon but can manifest as nosocomial 
pneumonia, infections  associated with continous ambulatory peritoneal 
dialysis or catheter associated bacteriuria. The characteristics by which 
presumptive identification can be made are 
 Appear as cocci or coccobacilli in gram stain 
 Grow well on MacConkey agar- colonies have a slightly pinkish tint 
 Donot produce cytochrome oxidase 
 Exhibit rapid utilization of glucose with the production of acid 
 Exhibit rapid utilization of 10% lactose with the production of acid 
 Are nonmotile 
 Are penicillin resistant. 32 
Acinetobacter baumanii is a multidrug resistant organism  sensitive to 
relatively few antibiotics. A.baumannii is inherently resistant to many 
antibiotics and multidrug resistant Acinetobacter is not a new or emerging 
phenomenon. The antibiotics that are usually effective are imepenem, 
meropenem, cefepime,  piperacillin , tazobactam and polymyxinB. 1 The use 
of ceftazidime and cefotaxime was associated with an increased risk of 
nosocomial pneumonia with resistant strains of A.baumannii. Prevention of 
recurrent MDR A.baumannii infections was achieved  after discontinuation of  
cefotaxime in ICUs. 29 
 OF – Glucose of     OF – Glucose of 
A.baumannii              A.lwofii 
 
 
 
 
 
 
 
Biochemical reactions of Acinetobacter 
 
 
 
 
 
 
 
TSI, Citrate, Indole, Urease, OF-Glucose 
 Characteristics of Acinetobacter 
Acinetobacter 
Test 
A.baumannii A.lwofii 
Oxidase - - 
Motility - - 
Growth on Macconkey + + 
OF-glucose A - 
Nitrate reduction - - 
 
+ , 90% (or) more strains positive / - , 90% (or) more strains negative / A , acid 
reaction.            
STENOTROPHOMONAS 
The Genus  Stenotrophomonas was created in 1993 to accommodate 
S.maltophilia. Now in addition, 4 new species have been identified 
 S.africana 
 S.nitritireducens 
 S.acidaminiphila 
 S.rhizophila 
S.maltophilia is a motile rod with polar  multitrichous flagella and is 
oxidase negative and lysine decarboxylase positive.33 S.maltophilia is 
ubiquitious and occasionally causes opportunistic infections and is emerging 
as an important hospital acquired pathogen. S.maltophilia is the third most 
frequently encountered non-fermenter in clinical laboratories. 49 The most 
common site for recovery is the respiratory tract, although in most patients 
these isolates do not appear to be clinically significant. Risk factors 
associated with death for patients with S.maltophilia isolate include  
  Patient in ICU 
 Age older than 40 yrs 
 Mechanical ventilator support. 49 
S.maltophilia exhibit unique antibiotic susceptibility  profile- it is 
inherenty resistant to most commonly used antipseudomonal drugs including 
aminoglycosides and many beta-lactam agents used against P.aeruginosa. 
Interestingly, S.maltophilia is inherently susceptible to trimethoprim-
sulfamethoxazole, a drug that has no activity against P.aeruginosa. 
The characteristics by which presumptive identification can be made are 
 Good growth on blood agar and MacConkey agar 
 Do not produce cytochrome oxidase 
 Produce acid in OF maltose but may be negative in OF glucose 
 Lysine decarboxylase positive 
 DNAse positive 
 Some strains show yellow pigment 
Characteristics of Stenotrophomonas maltophilia and Burkholderia 
cepacia complex 
 Test S.maltophilia B.cepacia complex 
Oxidase - + (93) 
Motility + + 
Growth on Macconkey + + 
OF-glucose A/Weak A 
Nitrate reduction V(42) V (37) 
Nitrate to gas - - 
Lysine + + 
Polymyxin B S R 
+ , 90% (or) more strains positive / - , 90% (or) more strains negative / V , 11 – 89 % 
of strains positive / A – acid reaction / ( ) numbers in the parenthesis are % of strains 
giving positive/ S- Susceptible / R-Resistant  
 ALCALIGENES 
Alcaligenes faecalis is the most frequently isolated member of this 
Genus. Members of this species produce strong alkaline reactions in all 
carbohydrate media. A key biochemical feature of this species is its ability to 
reduce nitrite but not nitrate. A.faecalis exist in soil and water and causes 
opportunistic infections like acute otitis media, urinary tract infection and 
bacteremia. It is often found in mixed cultures, particularly in samples of 
diabetic ulcers of foot and its clinical significance is difficult to determine.33 
BURKHOLDERIA 
In the past they have been referred to as Pseudomallei group. All the 
species in this group are easily separated from other group of Pseudomonads 
by the property of exhibiting resistance to polymyxin group of antibiotics 
(PolymyxinB and colistin). Two of the pathogenic species are B.mallei and  
B.pseudomallei.33 
B.mallei is a small gram-negative coccobacilli and it is the only non-
motile species in the genus. It is an obligate parasite of animals causing 
respiratory tract infection known as glanders. B.pseudomallei causes 
melioidosis which has been known as “Vietnamese time bomb” due to its 
ability to produce latent infections which can be reactivated many years after 
primary exposure.16 Infections are acquired either by inhalation or direct 
contact through breaks in the skin.33 Three forms of melioidosis are known 
 Acute disease – presenting as septicemia with metastatic lesions 
 Sub-acute disease- presenting as TB like pneumonia with cellulitis and 
lymphangitis 
 Chronic disease- presenting as localized chronic cellulitis. 
 Diabetes mellitus is an important risk factor for development of 
bacteremic melioidosis.53 The mortality rate is 95% in patients with acute 
disease who are not treated. B.pseudomallei is inherently resistant to many 
antibiotics including penicillins, first and second generation cephalosporins, 
macrolides, rifamycins, colistin and aminoglycosides51. This unusual antibiotic  
profile–gentamycin and colistin resistant and amoxycillin-clavulanate 
susceptible, in an oxidase positive gram-negative bacilli is useful for 
confirming the identification of B.pseudomallei. The organism grows readily on 
most of routine laboratory media and can be recovered from blood using 
standard blood culture technique. Selective agar either Ashdown’s selective 
agar or B.pseudomallei selective agar or selective broths are recommended  
for isolation of B.pseudomallei from nonsterile body sites like sputum in a 
clinically suspected case of melioidosis. Commercial systems like Vitek 1&2, 
API 20NE, API 20E are available for identification of B.pseudomallei. 33 
B.cepacia 
B.cepacia is a phytopathogen that causes onion bulb rot in plants and 
foot rot in humans. Since, early 1980s, B.cepacia has emerged as a cause of 
opportunistic human infections, particularly in patient’s with chronic 
granulomatous disease and cystic fibrosis41,42. Recent taxonomic advances 
demonstrate that B.cepacia is actually a cluster of atleast 9 closely related 
genomic species, now called B.cepacia complex which includes B.cepacia 
(genomovar1), B.multivorans (genomovar2), B.cenocepacia (genomovar3), 
B.stabilis (genomovar4), B.vietnamiensis (genomovar5), B.dolosa 
(genomovar 6), B.ambifaria (genomovar7), B.anthina (genomovar 8) and 
B.pyrrocinia (genomovar 9). These bacteria are associated with “cepacia  
syndrome” manifested as severe progressive respiratory failure and 
 bacteremia. Disinfectants in which B.cepacia will grow include povidone-
iodine, quaternary ammonium compounds and chlorhexidine. It also grow in 
distilled water with nitrogen source owing to the ability of the organism to fix 
CO2 from air. Selective media with bacteriostatic dyes, antibiotics or low pH 
have been described for selective isolation of  B.cepacia. These include 
Pseudomonas cepacia medium(PCM) containing crystal violet, polymyxin B 
and ticarcillin,OFPBL medium containing polymyxinB, bacitracin and lactose 
and B.cepacia selective agar(BCSA) containing lactose, sucrose, polymyxinB, 
gentamicin and vancomycin. Unlike other common pseudomonads, B.cepacia 
is resistant to aminoglycoside antibiotics but is usually susceptible to 
trimethoprim-sulfamethoxazole, which has become the drug of choice in 
treating B.cepacia infections. 33 
B.gladioli 
Formerly known as Pseudomonas marginata. It is primarily a plant 
pathogen causing flower rot in gladiolus and other plants. It is oxidase 
negative and produces non-fluorescent yellow colonies. It has been reported 
to cause human pulmonary disease and sometimes bacteremia and soft 
tissue infection in patients with cystic fibrosis, chronic granulomatous disease, 
diabetes mellitus and other immunological deficiencies.12,50 Molecular 
methods are more reliable when confirmation of an isolate as B.gladioli is 
deemed necessary. The antibiotic susceptibility pattern may also serve as a 
clue that an organism might be B.gladioli, since it tends to be susceptibile to 
aminoglycosides, meropenem, ciprofloxacin and trimethoprim-
sulfamethoxazole and resistamt to aztreonam and cephalosporins. 33 
 Characteristics of Burkholderia mallei and  
Burkholderia pseudomallei 
Test B.mallei B.pseudomallei 
Oxidase V + 
Motility - + 
Growth on Macconkey agar V + 
OF-glucose A A 
Nitrate reduction + + 
Nitrate to gas - + 
Agrinine + + 
Polymyxin B R R 
 
+ , 90% (or) more strains positive / - , 90% (or) more strains negative / V , 11 
– 89 % of strains positive / A - acid reaction / R – Resistant. 
FAMILY FLAVOBACTERIACEAE 
Most species in this family produce yellow-pigmented colonies on 
blood agar plate and all are oxidase positive. All species are non-motile and 
negative for nitrate reduction and most species fails to grow on MacConkey 
medium. The organisms previously included in the Genus Flavobacterium are 
now classified in the Genus Chryseobacterium, Sphingobacterium and 
Empedobacter.56 Chryseobacterium meningosepticum is the species most 
often associated with significant disease in humans. It has been reported to 
cause pneumonia, endocarditis, wound infection, postoperative bacteremia 
and meningitis.44 It is highly pathogenic for premature infants and has been 
associated with neonatal meningitis. They are isolated from soil, plants, water, 
food-stuffs, hospital water sources including incubators, sinks, tap water, 
haemodialysis system and saline solution.32 
 C.meningosepticum 
Biochemical reactions and colonies on  
nutrient agar 
 
 
 
 
 
 
 
 
 Characteristics of indole positive group 
Chryseobacterium EmpedobacterTest 
C.meningo
septicum 
C.gleum C.indologenes E.brevis 
Oxidase + + + + 
Motility - - - - 
Growth on 
Macconkey 
V (26) V (50) - - 
OF – glucose A A A V (80) 
Indole + + + + 
Nitrate to nitrite - V (67) V (14) - 
Nitrate to gas NA + - - 
Polymyxin B R R S (3%) R 
+ , 90% (or) more strains positive / - , 90% (or) more strains negative / V , 11 
– 89 % of strains positive / A – acid reaction / ( ) numbers in the parenthesis 
are % of strains giving positive/ S- Susceptible / R-Resistant  
METHODS FOR IDENTIFICATION USING CONVENTIONAL TESTS 
WEYANT(CDC), GILARDI AND PICKETT IDENTIFICATION SCHEMES 
If an unknown  NFGNB is not P.aeruginosa, A.baumannii or 
S.maltophilia, additional characteristics must be determined to make a 
species identification. Several schemes are currently being used in clinical 
laboratories. The schemes designed by Pickett, Gilardi and Weyant and 
associates have the largest database. 
CDC SCHEME-WEYANT AND ASSOCIATES 
            In answer to the problem of how to identify NFs in the clinical 
laboratory without doing all the tests that are done in a reference laboratory, 
Weyant and colleagues have published a three-part guide that includes 
 
           -An identification key for gram-negative aerobes 
         - A set of 12 identification tables 
         - A numerical code book by which derived biotype members can be 
linked to species name. 
To correctly interpret the results from a given identification table, one 
must use the same procedures on which the reactions are based.32 
THE GILARDI SCHEME 
The Gilardi approach is based on two fundamental principles that have 
made it practical for use in clinical laboratories 
The media and tests are readily available in most clinical laboratories 
and frequently the same as those used for identification of other groups of 
bacteria including Enterobacteriaceae, 
Identification of  most clinical isolates can be made in 2 stages-
1.through the use of a primary battery of media and reactions that are 
sufficient in the majority of cases and 2.a secondary battery, available when 
the first is inadequate. 32 
THE PICKETT SCHEME 
Pickett was among the first to bring some order to the identification of 
NFs. His system was designed to identify rapidly the two most frequently 
recovered NFs-P.aeruginosa and A.baumannii. Pickett advocated the use of a 
heavy inoculum prepared in an aqueous suspension from overnight growth of 
bacteria that was inoculated into buffered single substrates for testing the 
acidification of carbohydrates the alkanization of amides and organic salts. 32 
 COMPUTER AIDED SYSTEMS 
BioBASE is a DOS-based computer program for computer-aided 
identification of microorganisms. The system enables the user to create and 
access hundreds  of  microbial databases and switch between them, 
depending on the primary characteristics of the microbial isolate being 
studied. Included with this software is the database that includes 66 taxa of 
NFs identified using 83 phenotypic tests. 
PIBWIN(Probabilistic Identification of Bacteria for Windows) 
This program provides probabilistic identification of unknown bacterial 
isolates against identification matrices of known strains. The program has 3 
major functions 
           1.Identification of an unknown isolate 
           2.the selection identification is not achieved 
          3.Storage and retrieval of results. 32 
COMMERCIAL KIT SYSTEMS 
Packaged kit systems have been designed for or adapted to the 
identification of NFGNB. These kits share many of attributes of packaged 
systems ingeneral. Packaged systems have found wide acceptance in clinical 
laboratories for the following reasons 
1. their accuracy has proved to be comparable with that of conventional 
identification systems 
 2. several of the systems have a long shelf-life-6 months to 1 year, so that 
outdating of media, a problem particularly with conventional systems is 
minimized. 
3. the system requires only a minimum of space for storage and incubation. 
4. some of these systems are as easy or easier to use than the conventional 
methods. Inoculation is simple, reactions are generally clear cut within 24 
hours and the availability of computer-assisted file registers make final 
identification easy and accurate. 
These kits include various substrates like nitrate reduction, 
tryptophanase, glucose fermentation, arginine dihydrolase, urease, esculin 
hydrolysis, gelatinase and beta-galactosidase. 
Inherent problems in the use of many of the currently available 
packaged kits for identifying NFs include the  
1. tendency for organisms that exhibit weak or delayed biochemical activity 
to produce false negative results 
2. less than optimal design of many systems for the cultivation of certain 
NFs 
3. inclusion of some differential tests that may not be applicable to 
identification of NFs. 32 
Various kit systems available are 
- Oxi-Ferm tube 
- API 20E 
- API 20NE 
 - Remel uni-N/F system 
- Crystal Enteric/Non-fermenter system 
- RapID NF plus 
- Biolog system  
AUTOMATED IDENTIFICATION SYSTEMS 32 
VITEK 2 SYSTEM 
It is an integrated modular system that consists of a filling-sealer unit, a 
reader incubator, a computer control module, a data terminal and a multicopy 
printer. The new card contains 47 tests and the database for the new card has 
been expanded to 159 taxa compared with only 101 for the original vitek 2 
card. Vitek 2 card correctly identified 92.4% NFs to the species level. 
THE VITEK LEGACY SYSTEM 
         The vitek legacy system has been used with success in the identification 
of NFs most frequently encountered in the clinical laboratory. Correct 
identification to the species level at initial testing was 71.8%, improving to 
92.3% after additional testing was performed as recommended by 
manufacturer’s protocol. 
THE MICROSCAN WALKAWAY-96,WALKAWAY-40 AND AUTOSCAN-4SYSTEM 
It is a fully automated instrument. Walkaway-96 rapid gram-negative 
panel is reported to correctly identify 92.3% of non-enteric bacilli. The 
walkaway system correctly identified 71.4% of isolates to species level at 
initial testing, improving to 96% after additional tests. 
 THE SENSITITRE AP80 SYSTEM 
It is an automated system that uses fluorescence technology to detect 
bacterial growth and enzyme activity. It consists of 32 biochemical tests, each 
test medium along with an appropriate fluorescence indicator is dried into the 
individual well. Results are transmitted to a computer for analysis and 
identification. It permits identification of GNB in as little as 5 hours, with the 
option of additional overnight incubation if needed or desired. Correct 
identification was obtained for 95.1% of all NFs tested. 
THE PHOENIX SYSTEM 
It is a newly developed, fully automated, identification and antimicrobial 
susceptibility testing system. It uses 45 biochemical substrates including 16 
fluorogenic, 14 fermentation, 8 carbon source, 5 chromogenic and 2 
miscellaneous substrates(urea and ornithine) with vast majority of results 
provided in 4 hours or less. 89.3% of correct identification is obtained with this 
system. 
MOLECULAR METHODS 
Various molecular methods like in-situ hybridization and nucleic acid 
amplification techniques like PCR is used for direct detection of pathogenic 
bacteria (like P.aeruginosa, B.cepacia, S.maltophilia) in clinical specimens. It 
demonstrated 90% sensitivity and 100% specificity compared with culture, 
even in the complicated milieu of respiratory specimens from patients with 
cystic fibrosis. Nucleic acid amplification techniques are also useful for 
detection of genes (those producing MBL) responsible for drug resistance. 
 Genotyping of P.aeruginosa can be done by Random Amplified 
Polymorphic DNA (RAPD) analysis, Pulsed-field gel electrophoresis (PFGE) 
and amplified fragment length polymorphism (AFLP). 52 
Genes for detection of MBL in P.aeruginosa 
Multiplex PCR for detection of blaIMP and blaVIM MBL genes can be 
carried out using the IMP-DIA (forward, 5’ – GGA ATA GAG TGG CTT AAT 
TCT C; reverse, 5’ GTG ATG CGT CYC CAA YTT CAC T) and VIM – DIA 
(Forward, 5’ – CAG ATT GCC GAT GGT GTT TGG; reverse, 5’ – AGG TGG 
GCC ATT CAG CCA GA) Primers. 34 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims and Objectives 
  
 
AIM AND OBJECTIVE OF THE STUDY 
 
 To isolate non-fermentative Gram negative bacilli in various clinical 
samples processed from patients admitted in Intensive Care Unit in 
Government Stanley Hospital. 
 To establish the significance of their isolation. 
 To study the susceptibility pattern of these organisms to institute early 
and effective treatment. 
 To find out the emerging pattern of resistance in these organisms by 
phenotypic methods. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and 
Methods  
 MATERIALS AND METHODS 
STUDY DESIGN : Descriptive study  
The study was conducted in the department of microbiology, 
Government Stanley Medical College and Hospital. 
STUDY  PERIOD 
Over a period of one year from June 2006-May 2007 
SAMPLE SPECIFICATION 
Samples were collected from 100 cases admitted to ICU with the 
following criteria 
INCLUSION  CRITERIA 
1. All patients admitted to ICU developing infective symptoms. The 
patients were closely monitored for any evidence of clinical 
manifestations suggestive of infections viz, fever, leukocytosis, 
leucopenia, purulent endotracheal secretions, copious wound 
discharge, recent radiological infiltrates in chest X-ray etc.  
2. Non-fermenters isolated from two consecutive samples were included 
in the study. 
EXCLUSION CRITERIA 
1. Patients who were admitted to the ICU following prior stay in other 
wards of the hospital. 
 2. Patients admitted in the ICU following more than 24hrs of stay in 
neighouring hospitals. 
3. Non-fermenters not isolated from two consecutive samples were 
excluded from the study.  
METHODOLOGY 
SPECIMEN 
Appropriate clinical sample based on the clinical manifestations like 
pus, sputum, blood, urine, CSF, endotracheal aspirates were collected taking 
adequate aseptic precautions. A total of 135 samples were collected from 100 
patients which includes - pus(33), sputum(25), urine(31), blood(25), 
endotrcheal aspirate(10), CSF(5), pleural fluid(5), bronchoalveolar lavage(1). 
SPECIMEN COLLECTION 
Sputum 
The patients were instructed what constituted a proper sputum 
specimen and explained how it should be produced from the depth of chest. 
The patient was asked to expectorate 5-10ml of sputum directly into a sterile 
container, as far as possible without spoiling the outer surface. If spoiled, after 
tightly closing the container the outer surface was wiped with cotton dipped in 
70% alcohol. 
Urine- clean catch, midstream urine in non-catheterised patients 
In case of indwelling catheter, tubing was clamped off above the port to 
allow collection of freely voided urine. The catheter port (or) wall of the tubing 
was then cleaned vigorously with 70% ethonal and urine was aspirated via a 
 needle and syringe; the integrity of the closed drainage system was 
maintained to prevent the introduction of microorganisms. 
Pus Specimen 
The wound margins were decontaminated with spirit and a deep wound 
swab taken, taking care not to touch the adjacent skin margins. The swab was 
then introduced into sterile test tube and transported immediately to the 
diagnostic laboratory. Two swabs were collected from each wound and one 
was subjected to gram stain and the other for culture studies. 
Blood Sample 
The vein from which blood is to be withdrawn was selected and the 
skin site was disinfected with betadine and 70% alcohol to reduce the risk of 
introducing contaminants. About 5 ml of blood was collected and transferred 
to 50 ml of Brain-Heart infusion broth. 
Cerebrospinal Fluid 
CSF was collected by aseptically inserting the needle into the sub-
arachnoid space, usually at the level of lumbar spine. A minimum of 5-10 ml 
was collected into a sterile test tube. It was delivered immediately to the 
laboratory for detection of microorganisms by centrifugation and culture. 
Bronchoalveolar Lavage 
A deeper sampling of desquamated host cells and secretions can be 
obtained by  BAL. During this procedure, a high volume of saline (100-300ml) 
is infused into a lung segment through the bronchoscope to obtain cells and 
protein of pulmonary interstitium and alveolar spaces. It is estimated that 
 more than 1 million alveoli are sampled during this process. BAL has been 
shown to be safe and practical method for diagnosing opportunistic pulmonary 
infections in immunosuppressed  patients. 
Endotracheal Aspirate 
Collected in a sterile container under aseptic precautions. 
PRELIMINARY ENAMINATION OF SPECIMEN 
All the specimens collected were examined for macroscopic 
characteristics like color, consistency, odor, presence of blood and they were 
recorded. 
MICROSCOPIC EXAMINATION 
All the specimens were subjected to Gram staining and the presence of 
organisms, pus cells and other cells were noted. 
PRIMARY CULTURE 
Urine, Sputum, Pus, Endotracheal Aspirate ,Bal 
Each sample was inoculated into Blood agar (BAP), Macconkey agar 
and Nutrient agar and incubated aerobically at 37oC for 24 hours.  
CSF 
Two or three loopful of centrifuged sediment was placed on each 
culture medium and incubated aerobically at 37oC for 24hours. 
 Blood 
After 48 hours of enrichment in brain-heart infusion broth, subculture 
was made on BAP and MacConkey agar. 
BASIC APPROACH FOR IDENTIFICATION OF NON-FERMENTERS 
1. All non-lactose fermenting colonies on MacConkey with smooth 
colonies on BAP were considered significant. 
2. Tiny colonies on BAP with poor or no growth on MacConkey were 
considered significant. 
These isolates were then subjected to  
               -Gram stain and 
              - Inoculated in Triple sugar iron agar (TSI) 
All GNB which lacks acid production in TSI manifested as alkaline slant 
and an alkaline deep reaction AK/AK or alkaline slant and no change reaction 
AK/- considered as NFGNB and preserved for further identification tests. 
IDENTIFICATION OF ISOLATES 
Once a ten isolates of NFGNB were isolated, they were subjected to 
various biochemical tests for speciation. The tests include 
 Motility 
 Oxidase 
 Indole production 
 Hugh-Leifson Oxidation-Fermentation test 
  
 
 
 
 
Biochemical reactions for identification of non-fermenters 
 
 
 
 
 
 
 
 
 
 
 
 
TSI / Citrate / Indole / OF-Glucose / OF – Lactose / OF – Sucrose / 
 OF- Maltose / OF- Mannitol / OF – Xylose / Nitrate reduction 
/ Lysine, Arginine, Ornithine   Decarboxylase  
  
 
 
 
Biochemical reactions  
 
Pseudomonas                     Acinetobacter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pseudomonas – TSI- K/K, Citrate – Positive, Indole – Negative , Urease 
– Negative, Nitrate reduction – Positive  
 Acinetobacter – TSI – K/K, Citrate – Negative, Indole – Negative, 
Urease – Positive, Nitrate reduction - Negative  
  
OF-Reactions 
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Acinetobacter 
 
 
 
 
 
 
 
 
 
 
OF-Glucose, OF-Lactose, OF-Sucrose, OF-Maltose, 
OF-Mannitol, OF-Xylose 
 
 
Shewanella  Putrefaciens 
Biochemical reactions 
  
 
 
 
 
 
 
 
Colonies on Blood agar 
OF-Glucose, OF-Lactose, OF-Sucrose, OF-
Maltose, OF-Mannitol, TSI, Citrate, Indole 
  Lysine, Arginine, Ornithine decarboxylase test (LAO) 
 Citrate utilization 
 Nitrate reduction 
 Urease production 
 Pigment production 
ANTIMICROBIAL SUSCEPTIBILITY TESTING 
After isolating and identifying the organism their antimicrobial 
susceptibility testing was performed by Kirby-Bauer disc diffusion method. 
The test was performed on Muller-Hinton agar (MHA) using commercially 
available discs. Turbidity of actively growing broth culture was adjusted so 
that it is optically comparable to that of 0.5 McFarland standard. A sterile 
cotton swab was dipped into the suspension and was pressed firmly on the 
side wall of test tube above the fluid level to drain the excess fluid. The dried 
surface of MHA was inoculated by streaking the swab over the entire sterile 
agar surface. This procedure was repeated by streaking two more times 
rotating the plate approximately 60 degrees each time to ensure an even 
distribution of inoculum. The predetermined battery of antimicrobial discs 
which included Ciprofloxacin, Amikacin, Gentamycin, Piperacillin-
Tazobactam, Meropenem and Ceftazidime was dispensed onto the surface of 
inoculated agar plate. The discs were evenly distributed so that they were not 
closer than 24mm from center to center. The plates were incubated 
aerobically at 37oC for 16 to 18 hours. After this period, each plate was 
examined and if the plate was satisfactorily streaked and the inoculum was 
correct, the resulting zones of inhibition will be uniformly circular and there will 
be confluent lawn of growth. The diameter of zones of inhibition was 
measured including the diameter of disc. The zone size were interpreted by 
 referring to NCCLS standards and reported as either susceptible, intermediate 
or resistant. 
Controls used with each batch- P.aeruginosa ATCC 27853. 
DETERMINING THE SIGNIFICANCE OF THE ISOLATES 
The pathogenicity and significance of all the NFs isolated from the 
patients was confirmed by repeat isolation of the organism by obtaining a 
second sample from the same patient. 
DETECTION OF METALLO BETALACTAMASES 
Double disc synergy using meropenem and EDTA discs or ceftazidime 
and EDTA discs was used to screen MBL.  
Zone enhancement with EDTA impregnated meropenem and ceftazidime 
discs 
Test organisms were inoculated on to plates with MHA as 
recommended by NCCLS. A 0.5M EDTA solution was prepared by dissolving 
186.1 g of EDTA.2 H20 powder in 1000 ml distilled water and adjusting the pH 
to 8.0 by using NaOH. The mixture was sterilized by autoclaving. Two 10 
microgram of meropenem disc and two 30 microgram of ceftazidime disc 
were placed on the surface of an agar plate and EDTA solution was added to 
one of them to obtain a desired concentration of 750 micrograms. The 
inhibition zones of meropenem, ceftazidime and meropenem EDTA and 
ceftazidime EDTA discs were compared after 16-18 hrs of aerobic incubation 
in air at 35oc.   
 To test the stability of the EDTA added discs, an EDTA solution was 
added to 10 microgram meropenem disc and 30 microgram ceftazidime discs 
to obtain a concentration of 750 micrograms. The discs were dried 
immediately in an incubator and stored at 4oC (or) at – 20oC in an airtight vial 
without any desiccant. The inhibition zones produced for MBL-positive and 
MBL-Negative isolates were compared after storage of discs. 35,59 
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Results 
 RESULTS 
The study was performed during June 2006 to May 2007 at the 
Department of Microbiology, Government Stanley Medical College and 
Hospital. The study included 135 samples from 100 patients admitted to 
Intensive Care Unit. 
TABLE 1 
Percentage of  NFGNB among various Isolates 
Total No. of 
Samples 
Total No. (%) of  
NFGNB 
Total No. (%) of 
FGNB 
Total No. (%) of 
other isolates 
135 22 (16.3 %) 65 (48.15 %) 33 (24.44 %) 
 
GNB – Gram Negative Bacilli / NFGNB – Nonfermenting GNB /   
FGNB – Fermenting GNB/ Other isolates -Gram Positive Cocci (GPC), 
Diphtheroids, candida. 
 
Out of total 135 samples, NFGNB accounted for 16.3 % of isolates. 
This falls within 95% CI (10.8 – 23.3). FGNB accounted for 48.15% and 24.44 
% of isolates were found to be GPC,  Diphtheroids and candida. The 
remaining samples were culture negative (11.11%). 
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TABLE - 2 
Total number of isolates from various Clinical Samples  
(n = 135) 
SI Sample 
Total 
No.of 
Samples
Total 
No. of 
GNB 
Isolates
Total 
No. of 
NFGNB 
Total 
No. of 
FGNB 
Total 
No. of 
other 
Isolates 
NG 
1. Urine 31 24 5 19 3 4 
2. Sputum 25 12 3 9 12 1 
3. Pus 33 24 6 18 9 - 
4. Blood 25 15 3 12 6 4 
5. Cerebro spinal 
fluid (CSF) 
5 1 - 1 - 4 
6. Broncho 
alveolar lavage 
(BAL) 
1 1 1 - - - 
7. Endotracheal 
aspirate 
10 7 4 3 3 - 
8. Pleural fluid 5 3 - 3 - 2 
 
GNB – Gram Negative Bacilli  /  NFGNB – Nonfermenting GNB  /  FGNB –
Fermenting GNB / Others – (GPC), Diphtheroids, candida, NG-No Growth  
Out of 135 samples, 22 NFs were obtained which accounted for 16.3% of 
isolates. 
                     
                                
 TABLE – 3 
Total No.of various NFGNB Isolated from Clinical samples 
Sample 
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Pus 6 3 1 - - 1 1 
Sputum 3 3 - - - - - 
Urine 5 4 1 - - - - 
Blood 3 2 - 1 - - - 
Endotracheal 
Aspirate 
4 3 1 - - - - 
BAL 1 - - - 1 - - 
Total 22 15 3 1 1 1 1 
 
P.aeruginosa was the commonest isolates irrespective of the source and 
constitutes 68.18%. The next common isolate was P.fluorescens which 
constitutes 13.63%. The other NFs isolated were A.baumannii, A.lwofii, 
Chryseobacterium meningosepticum and Shewanella putrefaciens which 
constitutes 4.54% respectively. 
TABLE – 4 
Percentage of various NFGNB among the Isolates (n = 22) 
Organism Total No.Isolate Percentage 
P.aeruginosa 15 68.18 
P.fluorescens 3 13.63 
A.baumannii 1 4.54 
A.lwofii 1 4.54 
C.meningosepticum 1 4.54 
S.putrefaciens 1 4.54 
1 out of 9 samples collected from ICU were infected with P.aeruginosa. 
Infection with P.fluorescens was found in 1 out of 45 samples while only 1 out 
135 samples were infected with Acinetobacter and other NFs. 
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 TABLE – 5 
Antibiotic sensitivity profiles of various  
NFGNB (n = 22) 
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Pseudomonas 
(n = 18) 11 15 12 10 8 12 11 
Acinetobacter 
(n = 2) 2 2 2 2 1 2 2 
Others 
(n = 2)  
(Chryseobacterium 
& Shewanella) 
1 1 2 1 1 2 2 
 
TABLE - 6 
Antibiotic Profile of Pseudomonas Isolates (n = 18) 
Antibiotics Sensitive Intermediate Resistant 
Gentamycin 8 (44.44 %) 3 (16.66%) 7 (38.88 %) 
Amikacin 13 (72.22%) 2 (11.11%) 3 (16.66%) 
Ciprofloxacin 12 (66.66%) - 6 ( 33.33%) 
P/T 8 (44.44%) 2 (11.11%) 8 (44.44%) 
Cefotaxime 5 (27.77%) 3 (16.66%) 10 (55.55%) 
Ceftazidime 9 (50%) 3 (16.66%) 6 (33.33%) 
Meropenem 11 (61.11%) - 7 (38.88%) 
 
Table 5 & 6 
Amikacin was the highly effective drug with sensitivy of 83.33%. Next 
effective drugs were Ceftazidime and Ciprofloxacin with sensitivy of 66.7% 
and 66.6% respectively. Meropenem has a sensitivy of 61.1%. Cefotaxime 
was the least effective drug with the sensitivy of 54.4%. 
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TABLE – 7 
Total No.of MBL producers among various NFGNB (n = 22) 
Organism Total No. of Isolates MBL Producers 
Non -MBL 
producers 
Pseudomonas 18 7 (38.88%) 11 (61.11%) 
Acinetobacter 2 - 2 
Others 
(Chryseobacterium & 
Shewanella) 
2 - 2 
 
Out of 18 Pseudomonas isolates, 7 were found to be MBL Producing 
organisms which accounted for 38.88%. No MBL producing isolates were 
seen among other NFs. 
TABLE – 8 
Total No. of MBL producers among Pseudomonas 
Organism Total No. of 
Isolates 
MBL Producers Non-MBL 
producers 
P.aeruginosa 15 5 10 
P.fluorescens 3 2 1 
Total 18 7 11 
 
Out of 7 MBL producing Pseudomonas, 5 were P.aeruginosa and 
remaining 2 were P.fluorescens.  
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TABLE 9 
Zone enhancement of MBL producing Pseudomonas 
Organism 
Total 
No.of 
MBL 
producers
Zone 
enhancement 
with both 
CaEDTA / 
MeEDTA 
Zone 
enhancemen
t with 
CaEDTA only
Zone 
enhancement 
with MeEDTA 
only 
P.aeruginos
a 7 5 1 1 
 
CaEDTA – Ceftazidime EDTA disc, MeEDTA – Meropenem EDTA disc 
Screening for MBL production was done by Double-Disc synergy test 
using EDTA impregnated Meropenem and Ceftazidime disc. Of the 7 MBL 
producers, 5 isolates showed zone enhancement with both CaEDTA and 
MeEDTA. 1 isolate showed zone enhancement only with CaEDTA. The 
remaining 1 isolate showed zone enhancement with only MeEDTA. 
TABLE 10 
Percentage of isolates sensitive to different  betalactam  antibiotics 
among MBL producers and non-MBL producers 
 Cefotaxime Ceftazidime P/T 
MBL Producers 
(n = 7) 
28.57 % 57.14% 42.85% 
Non-MBL 
producers 
(n = 11) 
54.54% 72.72% 63.63% 
 
  
TABLE – 11 
Resistance of P.aeruginosa strains to meropenem, Ceftazidime (or) 
Ciprofloxacin according to previous therapy with meropenem / third 
generation Cephalosporins / Ciprofloxacin (or) any fluoroquinolone 
Previous 
therapy 
with 
meropenem
Previous therapy 
with 3rd 
generation  
Cephalosporins 
Previous therapy 
with 
fluoroquinolone 
Strain resistant 
 
No Yes No Yes No Yes 
To meropenem 3 4 4 3 2 5 
To Ceftazidime 4 2 3 3 2 4 
To Ciprofloxacin 5 1 2 4 1 5 
 
TABLE – 12 
Mortality Rates among hospitalized, critically ill patients with infections 
caused by MBL producing P.aeruginosa 
P.aeruginosa Total No.Isolates Mortality (%) of Patients 
MBL producers  7 4 (57.14%) 
Non-MBL producers 11 1 (9.09%) 
 
By Chi-square test, the mortality rate among MBL Producers is 
statistically significant when compared to Non-MBL producers. (P = 0.03) 
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Discussion 
 DISCUSSION 
In the present study, 100 patients admitted to ICU and developing 
symptoms suggestive of infections were investigated. Hospital-acquired 
infections pose a challenge to the ICU patients and threatens to undo the 
therapeutic advantages of life saving interventions undertaken by clinicians.9 
The present study obtained an isolation rate of 16.3% of non-
fermenters among the total samples and Pseudomonas sp accounted for 
13.3% of the infected patients which was observed in the studies of Richard 
MJ et al which showed an isolation rate of 13.2% to 44%.45 
Among the NFs isolated from clinical specimens, 81.8% were identified 
as Pseudomonas species. Study conducted by Yasodhara and Shyamala 
obtained an isolation rate of 76%.58 
In the present study an isolation rate of 68.18% of P.aeruginosa was 
obtained among NFs. The study of Kaushal et al showed an isolation rate of 
88.8% of P.aeruginosa. 36 The study conducted by Yasodhara and Shyamala 
obtained an isolation rate of 57% of P.aeruginosa. 58 Study conducted by 
Gladstone, Rajendaran and KN.Brahmadathan shows an isolation rate of 
42.8% of P.aeruginosa. 43 The above studies are almost in correlation with the 
present study. 
The present study showed an isolation rate of 13.63% of P.fluorescens. 
The other NFs isolated were A.baumannii, A.lwofii, Chryseobacterium and 
Shewanella species with an isolation rate of 4.54%. 
The study conducted by Veenu et al showed an isolation rate of 3.8% 
of P.fluorescens and 0.63% of A.baumannii and A.lwofii.57 Another study 
 conducted by Yashodhara and Shyamala showed an isolation rate of 8% of 
P.fluorescens and 13% of A.baumannii and 2% of A.lwofii. 58 
Maximum isolation rate of NFs were from endotracheal aspirate (40%), 
indicating that the commonest site of Pseudomonas infection in ICU patients 
was the respiratory tract. Second common specimen with maximum isolation 
was pus (18.18%). 
Next commonest sample with maximum isolation were urine (16.13%), 
blood (12%) and sputum (12%). Study conducted by Mishra et al found that 
most of the strains were from pus and blood. 58 
In our study sensitivity rate of Pseudomonas isolates to gentamycin 
was  61%, Amikacin - 83.33%, Ciprofloxacin – 66.6%, Piperacillin / 
Tazobactam – 55.6%, Cefotaxime – 54.4%, Ceftazidime – 66.7% and 
Meropenem – 61.1%. 
Amikacin (83.33%) was the highly effective anti-pseudomonal agent. 
This correlates with the study conducted by Nagoba et al which also showed 
amikacin as the most effective anti-pseudomonal agent. 6 The results of 
aminoglycoside sensitivity indicate that reistance to gentamycin is increasing. 
This correlates with the finding in the study conducted by Zheng YN et al. 60 
Out of 15 isolates of P.aeruginosa, 80% were found to be sensitive to 
amikacin, 66.6% to gentamycin, ciprofloxacin and meropenam, 60% to 
piperacillin-tazobactam, 73.3% to ceftazidime and 53.3% to cefotaxime. 
The study conducted by Nagoba et al which shows 97.7% of 
P.aeruginosa strains was sensitive to amikacin, 80% to ciprofloxacin and 
53.3% to gentamycin. 6 
 Sensitivity of P.aeruginosa to meropenem was 66.6% in our study. The 
study conducted by Sarkar et al showed a sensitivity rate of 59.09%25 and 
another study shows the sensitivity rate of 88% to Carbapenems. 43 Other NFs 
isolated in this study was sensitive to most of the antibiotics used like 
gentamycin, Amikacin, Ciprofloxacin, Ceftzadime and meropenem. 
The pseudomonas isolates of all species showed alarming levels of 
resistance to even the most recent antibiotics like third generation 
cephalosporins, anti-pseudomonal penicillins, aminoglycosides and 
fluoroquinolones. Resistance of such a high order could be because of 
unrestricted use of antibiotics. 
55.5% of pseudomonas isolates were found to exhibit multidrug 
resistance pattern- isolates resistant to two or more drugs. The study 
conducted by Veenu et al showed a multidrug resistant pattern with 65.3% of 
isolates.57 Similar view regarding the correlation between infection with 
P.aeruginosa and previous antibiotic use has also been reported by Bowton. 
This study documents a carbapenem resistance of 33.3% among 
P.aeruginosa and 38.9% of carbapenem resistance among all pseudomonas 
isolates. This is in contrast to the study conducted by Gladstone et al which 
documents 12.2% resistance to carbapenem.43 Study conducted by 
Navaneeth et al reported a prevalence of 12% carbapenem resistance. 39 
In view of the increasing reports of MBL production in pseudomonas, 
the isolates obtained in the present study were tested for the production of the 
same. 
Of the 18 isolates of pseudomonas, 7 showed resistance to 
meropenem by the double disc synergy method. All the 7 isolates exhibited a 
 significant zone size enhancement with the EDTA impregnated discs when 
compared with the plain antibiotic discs, which indicated MBL production by 
these isolates.  
5 out of 7 isolates had zone size enhancement with both ceftazidime 
EDTA and meropenem EDTA discs. The zone size enhancement was 5-
28mm for ceftazidime EDTA and 7-27mm for meropenemEDTA discs. 
One isolate exhibited a zone size increase only with ceftazidimeEDTA 
disc and one isolate only with meropenem EDTA disc. The remaining 11 
isolates were susceptible to meropenem and showed a zone size increase of 
only 0-5mm with EDTA impregnated antibiotic discs. 
In this study 38.9% of Pseudomonas isolates were found to be MBL 
producers. This is high when compared to 12% of MBL-mediated meropenem 
resistance in study conducted by Navaneeth et al.39 Another study conducted 
by Hemalatha et al showed 16% MBL production among pseudomonas. 26 
Study conducted by Sarkar et al. showed 54.5% of Pseudomonas isolates 
were MBL producers.   
Mortality rates among MBL Producers were 57.14% when compared to 
9.09% among Non-MBL producing P.aeruginosa. MBL production is a 
significant problem in hospital isolates of pseudomonas. With increasing use 
of carbapenems, the problem of MBL production is also increasing. The 
development of simple screening tests, designed to detect MBL production 
will be a crucial step towards large scale monitoring of these emerging 
resistant determinants. The use of EDTA impregnated antibiotic disc is a 
simple, easy to perform and cost effective test which can be conveniently 
used to screen carbapenem resistance. 26 
  
 
 
 
 
Summary 
 SUMMARY 
¾ The study was done at Department of Microbiology during June 2006 
to May 2007. In the Study 135 samples from 100 cases admitted to 
ICU developing symptoms suggestive of infections were collected and 
categorised. 
¾ By following routine standard isolation techniques, a total of 22 NFs 
(16.3%) were isolated from 135 clinical specimens. 
¾ P.aeruginosa was the commonest NF isolated, irrespective of clinical 
samples. 
¾ Though NFs are considered as opportunistic pathogens, it was 
observed in the present study, P.fluorescens, A.baumannii, A.lwofii, 
Chryseobacterium and Shewanella also could establish clinical 
infection like P.aeruginosa in immunocompromised patients. 
¾ Antibiotic susceptibility pattern was observed for these organism and it 
showed multidrug resistance pattern with majority of isolates being 
resistant to two (or) more drugs. 
¾ Screening for the production of MBL among Pseudomonas in this study 
revealed 38.9% were MBL producers. 
¾ The clinical outcome included in the study showed high rate of mortality 
(57.14%) among MBL producers than non-MBL producers and it was 
found to be statistically significant. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion  
  
CONCLUSION 
¾ Infections due to NFs pose a challenge to the ICU patients. 
¾ NFGNB, normally a saprophyte, cause serious infections in 
immunocompromised and hospitalized patients especially those 
admitted to ICU. 
¾ Of the various agents of NFs, Pseudomonas was the commonest 
organism to be isolated. 
¾ Multidrug resistant Pseudomonas were observed. Amikacin was the 
highly effective antibiotic against most of the isolates. 
¾ Increased incidence of MBL producing Pseudomonas had been 
observed. 
¾ Mortality rate were high among MBL producers than non-producers. 
  
 
 
 
 
Appendix 
 APPENDIX 
 
MacConkey agar  
This is a useful medium for the cultivation of enterobacteriaceae. It 
contains  a bile salt to inhibit non-intestinal bacteria and lactose with neutral 
red to distinguish the lactose-fermenting coliforms from the non lactose 
fermenting salmonella and shigella groups. The concentration of sodium 
taurocholate may be reduced to suit less tolerant organisms. The omission of 
sodium chloride from the medium prevents the spreading of proteus colonies. 
Peptone      20g 
Sodium taurocholate, commercial   5 g 
Water       1 litre 
Agar       20 g 
Neutral red solution, 2% in 50% ethanoal 3.5 ml 
Lactose, 10% aqueous solution   100 ml 
Dissolve the peptone and taurocholate (bile salt) in the water by 
heating. Add the agar and dissolve it in the steamer or autoclave. If 
necessary, clear by filtration. Adjust the pH to 7.5. Add the lactose and the 
neutral red, which should be well shaken before use, and mix. Heat in the 
autoclave with ‘free steam’ (c. 100o C) for 1 hr., then at 115o  C for 15 min. 
Pour plates. 
Nutrient agar  
     Gm/L 
Peptic digest of animal tissue 5.00 
Beef extract    1.50 
Yeast extract    5.00 
Agar     15.00 
 Dissolve the contents in water and mix by heating. Autoclave at 121o C 
for 15 minutes. Adjust pH to 7.4. Pour 20-25 ml of 9 cm dia. Petridishes to 
give 4 mm thickness. 
Blood agar 
Sterile sheep blood    50 ml 
Peptone     10 g 
Beef extract     3 g 
Sodium chloride    5 g 
Distilled water    1000 ml 
Autoclave the nutrient agar base at 121o C for 15 minutes and blood 
with sterile precautions and distribute in Petri dishes. 
Muller Hinton agar  
 Beef infusion 300 ml 
 Casein Hydrolysate 17 gm 
 Starch 1.5 gm 
 Agar 10 gm 
 Distilled water 1000 ml 
Emulsify the starch in a small amount of cold water, pour into the beef 
infusion and add the casein-Hydrolysate and the agar. Make up the volume to 
1000 ml (1 litre) with distilled water. Dissolve the constituents by heating 
gently at 100oC with agitation.  
Adjust the pH to 7.4. Dispense in screw-capped bottles and sterilize by 
autoclaving at 121o C for 20 minutes. 20 to 25 ml of it is poured into 
petridishes of 9 cm diameter to give a thickness of 4 mm. 
 McFarland’s Turbidity Standard for inoculum preparation 
A Barium sulphate 0.5 McFarland standard was prepared as follows 
1.  A 0.5 ml of 0.048 mol/L of Barium chloride was added to 99.5 ml of 
0.18 mol/L of H2SO4 with constant stirring to maintain a suspension. 
2.  Correct density of the turbidity standard was verified by using a 
spectrophotometer. The absorbance of 625nm should be 0.08 to 0.10 
for the 0.5 McFarland standards. 
3.  The Barium sulphate suspension was transferred in 4-6 ml to a screw 
capped tube of the same size as those used in growing or diluting the 
bacterial inoculum. 
4.  These tubes were tightly sealed and stored in the dark at room 
temperature. 
5.  The Barium sulphate turbidity standard was vigorously agitated before 
each use and inspected for a uniform turbid appearance. 
  
 
PROFORMA 
 
 
 
NAME   AGE   SEX 
 
COMPLAINTS 
 
PAST HISTORY  
 
 
H/O MECHANICAL VENTILATION  
 
H/O ANY SURGERY  
 
DURATION OF STAY IN HOSPITAL  
 
TREATMENT HISTORY (ANY ANTIBIOTICS GIVEN) 
 
CLINICAL FINDINGS  
 
 
DIAGNOSIS  
 
INVESTIGATIONS  
 
RESPONSE TO TREATMENT  
  
MASTER CHART 
 
Sl.No IP No Age/Sex Sample Organism G AK Cp P/T Ce Cz Me MBL Producers 
1 023503 23/F Blood 
*P.aeruginosa 
*P.aeruginosa 
R 
R 
S 
S 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
Positive 
2 071425 54/M Blood 
*P.aeruginosa 
*P.aeruginosa 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
Positive 
3 028627 33/M Blood 
*A.calcoaceticus 
*A.calcoaceticus 
S 
R 
S 
S 
S 
S 
S 
R 
R 
R 
S 
S 
S 
S 
Negative 
4 024414 16/M Pus 
*P.aeruginosa 
*P.aeruginosa 
S 
S 
S 
S 
S 
S 
S 
S 
R 
R 
S 
S 
S 
S 
Negative 
5 023081 52/M Pus 
*P.aeruginosa 
*P.aeruginosa 
S 
R 
S 
S 
S 
S 
S 
S 
R 
R 
S 
S 
S 
S 
Negative 
6 071665 17/F Pus 
*P.aeruginosa 
*P.aeruginosa 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
Positive 
7 071404 23/M Pus 
*P.fluorescens 
*P.fluorescens 
S 
S 
S 
S 
S 
S 
R 
R 
R 
R 
S 
S 
S 
S 
Negative 
8 023500 25/M Pus 
*C.meningosepticum 
*C.meningosepticum 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
Negative 
9 023444 75/F Pus 
*S.Putrefaciens 
*S.Putrefaciens 
R 
R 
R 
R 
S 
S 
R 
R 
R 
F 
S 
S 
S 
S 
Negative 
10 071005 16/M Sputum 
*P.aeruginosa 
*P.aeruginosa 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
Negative 
11 023810 29/M Sputum 
*P.aeruginosa 
*P.aeruginosa 
S 
R 
S 
S 
S 
S 
R 
R 
R 
R 
S 
S 
S 
S 
Negative 
12 023719 17/F Sputum 
*P.aeruginosa 
*P.aeruginosa 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
Negative 
13 018910 36/M Urine 
*P.aeruginosa 
*P.aeruginosa 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
Negative 
14 021110 17/F Urine 
*P.aeruginosa 
*P.aeruginosa 
S 
S 
S 
S 
S 
S 
S 
S 
R 
S 
S 
S 
S 
S 
Negative 
15 024211 42/M Urine 
*P.aeruginosa 
*P.aeruginosa 
R 
R 
S 
S 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
Positive 
16 071200 36/F Urine 
*P.aeruginosa 
*P.aeruginosa 
S 
R 
S 
S 
S 
S 
R 
R 
S 
R 
S 
S 
S 
S 
Negative 
17 025112 43/F Urine 
*P.fluorescens 
*P.fluorescens 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
Positive 
18 071311 17/M 
Endoracheal 
Aspirate 
*P.aeruginosa 
*P.aeruginosa 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
Negative 
19 023175 50/F E.aspirate 
*P.aeruginosa 
*P.aeruginosa 
R 
R 
S 
S 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
Positive 
20 071325 25/F E.aspirate 
*P.aeruginosa 
*P.aeruginosa 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
Negative 
21 024127 52/M E.aspirate 
*P.fluorescens 
*P.fluorescens 
R 
R 
S 
S 
S 
S 
S 
R 
R 
R 
S 
S 
R 
R 
Positive 
22 023317 40/M BAL 
*A.lwofii 
*A.lwofii 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
Negative 
 
G - Gentamycin,  AK - Amikacin,   Cp - Ciprofloxacin,  P/T – Piperacillin – Tazobactam,   
Ce – Cefotaxime,  Cz – Ceftazidime,  Me – Meropenem,   
*  -  Organisms obtained by repeat Isolation  
MBL – Metallo Beta Lactamases  
  
Sl.No IP.No Age / Sex Sample Organism isolated 
23 023085 15/F Blood K.pnemoniae 
24 023446 75/M Blood K.oxytoca 
25 071220 17/F Blood K.oxytoca 
26 071301 30/F Blood K.oxytoca 
27 071329 15/M Blood K.oxytoca 
28 024098 20/M Blood K.pnemoniae 
29 071453 22/M Blood K.pnemoniae 
30 021307 23/F Blood K.pnemoniae 
31 071458 17/F Blood P.aeruginosa 
32 071625 25/M Blood P.aeruginosa 
33 025098 29/M Blood E.coli 
34 071034 37/F Blood E.coli 
35 070883 31/M Blood Micrococcus 
36 071663 17/F Blood CONS 
37 025309 18/M Blood CONS 
38 024098 20/M Blood Micrococcus 
39 071427 49/M Blood NG 
40 071426 37/M Blood NG 
41 070982 42/M Blood NG 
42 023496 75/M Blood NG 
43 023028 47/M Blood CONS 
44 023812 28/M Blood CONS 
45 023446 75/M Pus P.mirabilis 
46 023452 30/F Pus P.mirabilis 
47 024215 73/M Pus P.mirabilis 
48 023085 15/F Pus P.vulgaris 
49 02342 28/M Pus P.vulgaris 
50 024213 73/M Pus P.vulgaris 
51 071220 17/F Pus P.vulgaris 
52 071301 30/F Pus P.vulgaris 
53 071329 15/F Pus P.aeruginosa 
54 024217 17/F Pus K.oxytoca 
55 071425 37/M Pus K.oxytoca 
56 071427 49/M Pus C.freundii 
57 071426 37/M Pus K.pneumonia 
58 071317 31/M Pus K.oxytoca 
59 071327 40/F Pus K.oxytoca 
60 070809 36/F Pus K.pneumonia 
61 023690 40/M Pus S.aureus 
62 070376 17/F Pus S.aureus 
 Sl.No IP.No Age / Sex Sample Organism isolated 
63 070936 51/F Pus CONS 
64 024431 37/M Pus Diphtheroids 
65 071493 25/M Pus CONS 
66 070883 52/F Pus CONS 
67 070310 52/F Pus Diphtheroids 
68 071034 37/F Pus P.aeruginosa 
69 04625 25/M Pus P.aeruginosa 
70 070710 44/F Pus Pneumococcus 
71 271506 78/M Pus Pneumococcus 
72 023812 28/M Sputum  K.oxytoca 
73 023496 75/M Sputum K.oxytoca 
74 023028 47/M Sputum K.pneumoniae 
75 02342 28/M Sputum K.pneumoniae 
76 028627 33/M Sputum K.pneumoniae 
77 023503 22/M Sputum Candida sp 
78 023747 16/F Sputum P.vulgaris 
79 021332 30/F Sputum P.mirabilis 
80 018912 38/M Sputum P.mirabilis 
81 023910 52/F Sputum P.mirabilis 
82 021124 74/M Sputum CONS 
83 024098 20/M Sputum CONS 
84 023446 75/M Sputum CONS 
85 023085 15/F Sputum CONS 
86 024213 73/M Sputum CONS 
87 024446 40/M Sputum Diphtheroids 
88 071223 19/F Sputum Diphtheroids 
89 025101 30/F Sputum S.aureus 
90 024110 17/M Sputum S.aureus 
91 023012 29/M Sputum S.aureus 
92 070661 30/M Sputum S.aureus 
93 022123 45/M Sputum NG 
94 071302 32/M Urine E.coli 
95 071450 40/F Urine E.coli 
96 024190 19/F Urine E.coli 
97 023080 51/M Urine E.coli 
98 023075 50/F Urine E.coli 
99 070300 23/F Urine E.coli 
100 071325 25/F Urine E.coli 
101 023494 55/F Urine E.coli 
102 023259 23/M Urine K.oxytoca 
103 024429 36/M Urine K.oxytoca 
 Sl.No IP.No Age / Sex Sample Organism isolated 
104 025101 40/M Urine K.oxytoca 
105 070911 50/F Urine K.pneumoniae 
106 024309 36/M Urine K.pneumoniae 
107 071401 42/F Urine K.pneumoniae 
108 071601 45/M Urine K.pneumoniae 
109 070880 52/M Urine P.aeruginosa 
110 025317 50/M Urine P.aeruginosa 
111 024127 52/M Urine P.vulgaris 
112 072011 23/M Urine P.vulgaris 
113 021122 41/F Urine Enterococci 
114 024185 42/M Urine Enterococci 
115 070111 51/F Urine Enterococci 
116 070890 21/F Urine NG 
117 024198 23/F Urine NG 
118 028520 25/M Urine NG 
119 025199 26/F Urine NG 
120 023081 17/F CSF NG 
121 071663 17/F CSF NG 
122 070982 42/M CSF NG 
123 071426 37/M CSF NG 
124 023912 71/F CSF K.pneumoniae 
125 021330 21/F Endotracheal swab K.pneumoniae 
126 071427 49/M Endotracheal swab K.pneumoniae 
127 070376 17/F Endotracheal swab K.oxytoca 
128 071223 19/F Endotracheal swab Diphtheroids 
129 022001 27/M Endotracheal swab CONS 
130 025211 32/F Endotracheal swab CONS 
131 023317 40/M Pleural fluid K.pneumoniae 
132 025121 40/M Pleural fluid K.pneumoniae 
133 018802 32/M Pleural fluid K.pneumoniae 
134 021998 23/F Pleural fluid NG 
135 072221 17/F Pleural fluid NG 
 
  
 
 
 
KEY TO MASTER CHART 
 
 
 
M   - Male 
F   - Female 
CSF   - Cerebrospinal Fluid 
K.pneumoniae - Klebsiella pneumoniae 
K.oxytoca  - Klebsiella oxytoca 
E.coli    - Escherichia coli 
CONS   - Coagulase Negative Staphylococcus 
P.mirabilis  - Proteus mirabilis 
P.vulgaris  - Proteus vulgaris 
NG   - No growth  
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